MX388869B - Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos. - Google Patents
Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos.Info
- Publication number
- MX388869B MX388869B MX2018000867A MX2018000867A MX388869B MX 388869 B MX388869 B MX 388869B MX 2018000867 A MX2018000867 A MX 2018000867A MX 2018000867 A MX2018000867 A MX 2018000867A MX 388869 B MX388869 B MX 388869B
- Authority
- MX
- Mexico
- Prior art keywords
- kits
- compositions
- capsular saccharide
- immunogenetic
- immunogenic compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
- C08H1/00—Macromolecular products derived from proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a nuevas composiciones inmunógenas que comprenden antígenos de sacárido capsular de Streptococcus pneumoniaeconjugados (glucoconjugados), kits que comprenden tales composiciones inmunógenas y sus usos; en general, las composiciones inmunógenas de la presente invención comprenden al menos un glucoconjugado de un serotipo de S. pneumoniae no encontrado en PREVNAR(r), SYNFLORIX(r) y/o PREVNAR 13(r); la invención también se refiere a la vacunación de sujetos humanos, en particular, niños y personas mayores, contra infecciones neumocócicas usando tales composiciones inmunógenas novedosas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562194965P | 2015-07-21 | 2015-07-21 | |
| PCT/IB2016/054217 WO2017013548A1 (en) | 2015-07-21 | 2016-07-18 | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018000867A MX2018000867A (es) | 2018-05-15 |
| MX388869B true MX388869B (es) | 2025-03-20 |
Family
ID=56507633
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018000867A MX388869B (es) | 2015-07-21 | 2016-07-18 | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos. |
| MX2021015775A MX2021015775A (es) | 2015-07-21 | 2018-01-19 | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021015775A MX2021015775A (es) | 2015-07-21 | 2018-01-19 | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos. |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US10124050B2 (es) |
| EP (2) | EP3325008B1 (es) |
| JP (4) | JP6994453B2 (es) |
| KR (4) | KR20250058066A (es) |
| CN (2) | CN122399004A (es) |
| AR (1) | AR105402A1 (es) |
| AU (2) | AU2016295566B2 (es) |
| BR (1) | BR112018000087A2 (es) |
| CA (1) | CA2936378A1 (es) |
| CO (1) | CO2018000503A2 (es) |
| ES (1) | ES3050314T3 (es) |
| HK (1) | HK1257816A1 (es) |
| IL (2) | IL303998A (es) |
| MX (2) | MX388869B (es) |
| MY (1) | MY192183A (es) |
| NZ (1) | NZ739007A (es) |
| PE (2) | PE20180657A1 (es) |
| PH (1) | PH12018500037A1 (es) |
| RU (1) | RU2721128C2 (es) |
| SG (1) | SG10202005253TA (es) |
| TW (4) | TWI684460B (es) |
| WO (1) | WO2017013548A1 (es) |
| ZA (2) | ZA201800197B (es) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4272750A3 (en) | 2013-02-07 | 2024-01-24 | Children's Medical Center, Corp. | Protein antigens that provide protection against pneumococcal colonization and/or disease |
| US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| BR112016015835B1 (pt) | 2014-01-21 | 2023-12-26 | Pfizer Inc | Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae |
| FI3583947T3 (fi) * | 2014-01-21 | 2023-10-12 | Pfizer | Streptococcus pneumoniaen kapselipolysakkaridit ja niiden konjugaatit |
| KR20250058066A (ko) * | 2015-07-21 | 2025-04-29 | 화이자 인코포레이티드 | 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도 |
| US10786561B2 (en) * | 2015-11-20 | 2020-09-29 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| US11058757B2 (en) | 2016-03-31 | 2021-07-13 | Pogona, LLC | Saccharide-polypeptide conjugate compositions and methods of use thereof |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| IL267709B2 (en) | 2016-12-30 | 2025-04-01 | Vaxcyte Inc | Polypeptide-antigen conjugates with unnatural amino acids |
| WO2018144439A1 (en) | 2017-01-31 | 2018-08-09 | Merck Sharp & Dohme Corp. | Methods for making polysaccharide-protein conjugates |
| CA3052621A1 (en) | 2017-02-03 | 2018-08-09 | Schadeck, Eva Barbara | Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof |
| JP7680185B2 (ja) * | 2017-02-24 | 2025-05-20 | メルク・シャープ・アンド・ドーム・エルエルシー | 肺炎連鎖球菌多糖-タンパク質コンジュゲートの免疫原性の増強 |
| WO2019050818A1 (en) | 2017-09-07 | 2019-03-14 | Merck Sharp & Dohme Corp. | METHODS OF FORMULATING PNEUMOCOCCAL POLYSACCHARIDES FOR CONJUGATION TO A CARRIER PROTEIN |
| MX2019014829A (es) | 2017-06-10 | 2020-08-17 | Inventprise Llc | Vacunas de conjugado multivalente con polisacáridos de conjugado bivalente o multivalente que proporcionan inmunogenicidad y avidez mejoradas. |
| US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
| US11524076B2 (en) | 2017-09-07 | 2022-12-13 | Merck Sharp & Dohme Llc | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
| US11395849B2 (en) | 2017-09-07 | 2022-07-26 | Merck Sharp & Dohme Llc | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
| HUE068482T2 (hu) * | 2017-09-07 | 2025-01-28 | Merck Sharp & Dohme Llc | Pneumococcus-poliszacharidok és azok felhasználása immunogén poliszacharid-hordozóprotein konjugátumokban |
| CA3074706A1 (en) * | 2017-09-07 | 2019-03-14 | Merck Sharp & Dohme Corp. | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
| CN111065387B (zh) | 2017-09-07 | 2023-08-25 | 默沙东有限责任公司 | 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途 |
| EP3691677A4 (en) | 2017-10-04 | 2021-07-07 | Pogona, Llc | COMPOSITIONS OF SACCHARIDE-POLYPEPTIDE CONJUGATES AND THEIR METHODS OF USE |
| EP3720483B1 (en) | 2017-12-06 | 2025-11-19 | Merck Sharp & Dohme LLC | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| JP7397000B2 (ja) | 2018-04-30 | 2023-12-12 | メルク・シャープ・アンド・ドーム・エルエルシー | 凍結乾燥変異ジフテリア毒素のジメチルスルホキシド中均一溶液を提供する方法 |
| WO2019212842A1 (en) * | 2018-04-30 | 2019-11-07 | Merck Sharp & Dohme Corp. | Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres |
| WO2019212846A1 (en) | 2018-04-30 | 2019-11-07 | Merck Sharp & Dohme Corp. | Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates |
| CN112969474A (zh) | 2018-09-12 | 2021-06-15 | 艾芬尼维克斯公司 | 多价肺炎球菌疫苗 |
| EP3897705A2 (en) | 2018-12-19 | 2021-10-27 | Merck Sharp & Dohme Corp. | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| CN110302375A (zh) * | 2019-06-27 | 2019-10-08 | 康希诺生物股份公司 | 一种糖缀合物及其用途 |
| GB201909393D0 (en) * | 2019-06-28 | 2019-08-14 | Gen2 Neuroscience Ltd | Tau epitope and binding molecules |
| CN112741901B (zh) * | 2019-10-31 | 2024-05-10 | 北京科兴中维生物技术有限公司 | 一种含有5型肺炎链球菌荚膜多糖的疫苗及其制备方法 |
| BR112022008761A2 (pt) * | 2019-11-22 | 2022-07-26 | Glaxosmithkline Biologicals Sa | Dosagem e administração de uma vacina de glicoconjugado de sacarídeo |
| WO2021229604A1 (en) * | 2020-05-14 | 2021-11-18 | Serum Institute Of India Private Limited | Methods for simultaneous fragmentation and purification of bacterial polysaccharides |
| IL300346A (en) * | 2020-08-07 | 2023-04-01 | Prothena Biosciences Ltd | TAU vaccine for the treatment of Alzheimer's disease |
| US12053515B2 (en) | 2020-08-10 | 2024-08-06 | Inventprise, Inc. | Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F |
| GB202016165D0 (en) | 2020-10-12 | 2020-11-25 | Optivalent Ltd | Vaccine |
| MX2024002779A (es) | 2021-09-09 | 2024-06-11 | Affinivax Inc | Vacunas neumocócicas multivalentes. |
| JP7747369B2 (ja) * | 2021-09-29 | 2025-10-01 | 北京大学 | 細菌莢膜オリゴ糖誘導体及びその製造方法、医薬組成物、使用 |
| GB2614916A (en) * | 2022-01-25 | 2023-07-26 | Optivalent Ltd | Intradermal vaccine complement |
| CN115671274B (zh) * | 2022-09-29 | 2024-03-12 | 普大生物科技(泰州)有限公司 | 一种载体蛋白与多糖共价键连接成结合物的方法及应用 |
| WO2024102751A2 (en) * | 2022-11-07 | 2024-05-16 | Southwest Research Institute | Lyophilized and stabilized live attenuated formulated vaccine against tularemia |
| WO2025219904A1 (en) * | 2024-04-19 | 2025-10-23 | Pfizer Inc. | Improved methods for producing glycoconjugates by reductive amination in aprotic solvent |
Family Cites Families (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4686102A (en) * | 1984-04-12 | 1987-08-11 | American Cyanamid Company | Multivalent pneumococcal vaccine and preparation thereof |
| US4709017A (en) | 1985-06-07 | 1987-11-24 | President And Fellows Of Harvard College | Modified toxic vaccines |
| US4950740A (en) | 1987-03-17 | 1990-08-21 | Cetus Corporation | Recombinant diphtheria vaccines |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| GB8815795D0 (en) | 1988-07-02 | 1988-08-10 | Bkl Extrusions Ltd | Glazing bead |
| NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
| CA2006700A1 (en) | 1989-01-17 | 1990-07-17 | Antonello Pessi | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
| AU651949B2 (en) | 1989-07-14 | 1994-08-11 | American Cyanamid Company | Cytokine and hormone carriers for conjugate vaccines |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| ATE128628T1 (de) | 1990-08-13 | 1995-10-15 | American Cyanamid Co | Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff. |
| EP0625910B1 (en) | 1992-02-11 | 2003-07-23 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Dual carrier immunogenic construct |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| JP3506431B2 (ja) | 1992-05-06 | 2004-03-15 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ジフテリア毒素受容体結合領域 |
| DE69313134T2 (de) | 1992-06-25 | 1998-02-26 | Smithkline Beecham Biolog | Adjuvantien enthaltende impfstoffzusammensetzung |
| IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| DK0616034T3 (da) | 1993-03-05 | 2005-02-21 | Wyeth Corp | Plasmid til fremstilling af CRM-protein og diphtheria toxin |
| KR100310510B1 (ko) | 1993-03-23 | 2002-07-04 | 장 스테판느 | 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물 |
| EP0720485B1 (en) | 1993-09-22 | 2003-11-19 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs |
| US5416349A (en) | 1993-12-16 | 1995-05-16 | National Semiconductor Corporation | Increased-density flash EPROM that requires less area to form the metal bit line-to-drain contacts |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US6455673B1 (en) | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
| US5917017A (en) | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
| AU713040B2 (en) | 1994-07-15 | 1999-11-18 | University Of Iowa Research Foundation, The | Immunomodulatory oligonucleotides |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| DE69628418T2 (de) | 1995-03-22 | 2004-04-01 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden |
| GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| AUPO517897A0 (en) | 1997-02-19 | 1997-04-11 | Csl Limited | Chelating immunostimulating complexes |
| CA2281838A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders |
| US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
| EP1003531B1 (en) | 1997-05-20 | 2007-08-22 | Ottawa Health Research Institute | Processes for preparing nucleic acid constructs |
| GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| EP1279401B1 (en) | 1997-09-05 | 2008-01-09 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
| US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
| US6218371B1 (en) | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| BR9909915A (pt) | 1998-04-09 | 2000-12-26 | Smithkline Beecham Biolog | Composições adjuvantes |
| GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
| ES2284287T3 (es) | 1998-10-16 | 2007-11-01 | Glaxosmithkline Biologicals S.A. | Sistemas adyuvantes y vacunas. |
| CA2355364C (en) | 1998-12-21 | 2014-03-18 | Medimmune, Inc. | Streptococcus pneumoniae proteins and immunogenic fragments for vaccines |
| PL205041B1 (pl) | 1998-12-23 | 2010-03-31 | Id Biomedical Corp | Izolowany polinukleotyd, wektor zawierający izolowany polinukleotyd, komórka gospodarza transfekowana lub transformowana za pomocą tego wektora, sposób wytwarzania polipeptydu kodowanego przez izolowany polinukleotyd, izolowany polipeptyd, chimeryczny polipeptyd, kompozycja do szczepionek zawierająca polipeptyd oraz jej zastosowanie w leczeniu lub zapobieganiu zakażeniu osobnika paciorkowcem |
| AUPP807399A0 (en) | 1999-01-08 | 1999-02-04 | Csl Limited | Improved immunogenic lhrh composition and methods relating thereto |
| DE60044236D1 (de) | 1999-02-17 | 2010-06-02 | Csl Ltd | Immunogene komplexe und methoden in bezug auf diese |
| US6936258B1 (en) | 1999-03-19 | 2005-08-30 | Nabi Biopharmaceuticals | Staphylococcus antigen and vaccine |
| CA2366152A1 (en) * | 1999-03-19 | 2000-09-28 | Smithkline Beecham Biologicals S.A. | Streptococcus pneumoniae vaccine |
| WO2000061761A2 (en) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| DK1187629T3 (da) | 1999-04-19 | 2005-01-17 | Glaxosmithkline Biolog Sa | Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid |
| HK1049106A1 (zh) | 1999-09-24 | 2003-05-02 | Smithkline Beecham Biologicals S.A. | 聚氧化乙烯山梨糖酯和octooxynol的聯用做為佐劑和其在疫苗中的用途 |
| IL148671A0 (en) | 1999-09-24 | 2002-09-12 | Smithkline Beecham Biolog | Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant |
| GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
| WO2001098334A2 (en) | 2000-06-20 | 2001-12-27 | Shire Biochem Inc. | Streptococcus antigens |
| GB0108364D0 (en) | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
| AU2002309706A1 (en) | 2001-05-11 | 2002-11-25 | Aventis Pasteur, Inc. | Novel meningitis conjugate vaccine |
| EP1425040A2 (en) | 2001-09-14 | 2004-06-09 | Cytos Biotechnology AG | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
| US7262024B2 (en) | 2001-12-20 | 2007-08-28 | Id Biomedical Corporation | Streptococcus antigens |
| MXPA05009579A (es) | 2003-03-13 | 2005-11-17 | Glaxosmithkline Biolog Sa | Proceso de purificacion para citolisina bacteriana. |
| EP1603950A2 (en) | 2003-03-17 | 2005-12-14 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
| GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
| EP1776105A2 (en) | 2004-07-18 | 2007-04-25 | Coley Pharmaceutical Group, Ltd | Methods and compositions for inducing innate immune responses |
| JP2008506789A (ja) | 2004-07-18 | 2008-03-06 | シーエスエル、リミテッド | インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物 |
| GB0421083D0 (en) | 2004-09-22 | 2004-10-27 | Glaxosmithkline Biolog Sa | Purification process |
| GB0428394D0 (en) * | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
| GB0502095D0 (en) * | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
| US20070184072A1 (en) | 2005-04-08 | 2007-08-09 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| IL308456A (en) | 2005-04-08 | 2024-01-01 | Wyeth Llc | A multivalent pneumomuroral protein-polysaccharide conjugate preparation |
| US7955605B2 (en) | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| PL1866342T3 (pl) | 2005-04-08 | 2019-04-30 | Wyeth Llc | Oddzielanie zanieczyszczeń od polisacharydu Streptococcus pneumoniae przez manipulację pH |
| HUE045482T2 (hu) * | 2005-06-27 | 2019-12-30 | Glaxosmithkline Biologicals Sa | Immunogén készítmény |
| JP5792920B2 (ja) * | 2005-12-22 | 2015-10-14 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
| TW200806315A (en) * | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
| CA2665169C (en) | 2006-10-10 | 2017-02-21 | Wyeth | Purification of streptococcus pneumoniae type 3 polysaccharides |
| HUE039169T2 (hu) | 2007-03-23 | 2018-12-28 | Wyeth Llc | Rövidített tisztítási eljárás Streptococcus pneumoniae tok-poliszacharidok elõállítására |
| JP2010525035A (ja) | 2007-05-02 | 2010-07-22 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
| CA2692069C (en) * | 2007-06-20 | 2016-10-18 | Baxter Healthcare S.A. | Modified polysaccharides for conjugate vaccines |
| EA200901578A1 (ru) | 2007-06-26 | 2010-08-30 | Глаксосмитклайн Байолоджикалс С.А. | Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae |
| DK2424562T3 (en) * | 2009-04-30 | 2015-12-07 | Coley Pharm Group Inc | Pneumococcal vaccine and uses thereof |
| WO2011041003A2 (en) * | 2009-06-22 | 2011-04-07 | Wyeth Llc | Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
| TW201136603A (en) * | 2010-02-09 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition |
| CN101785857B (zh) | 2010-03-05 | 2012-09-26 | 成都安特金生物技术有限公司 | 一种新的肺炎球菌结合疫苗及其制备方法 |
| WO2011130332A1 (en) * | 2010-04-12 | 2011-10-20 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
| US20130273098A1 (en) | 2010-12-10 | 2013-10-17 | Jeffrey T. Blue | Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions |
| GB201103836D0 (en) * | 2011-03-07 | 2011-04-20 | Glaxosmithkline Biolog Sa | Conjugation process |
| BR112013024322B1 (pt) * | 2011-03-22 | 2020-04-22 | Serum Inst India Ltd | processo para preparação de polissacarídeos |
| WO2013131983A1 (en) * | 2012-03-07 | 2013-09-12 | Novartis Ag | Adjuvanted formulations of streptococcus pneumoniae antigens |
| KR102057217B1 (ko) * | 2012-06-20 | 2020-01-22 | 에스케이바이오사이언스 주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| PT2885007T (pt) * | 2012-08-16 | 2018-12-10 | Pfizer | Processos e composições de glicoconjugação |
| CN103656631B (zh) * | 2012-09-24 | 2015-08-19 | 北京科兴中维生物技术有限公司 | 多价肺炎球菌荚膜多糖-蛋白缀合物组合物及其制备方法 |
| GB201218660D0 (en) * | 2012-10-17 | 2012-11-28 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| WO2014060385A1 (en) * | 2012-10-17 | 2014-04-24 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| KR20140075201A (ko) * | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| RU2672053C2 (ru) | 2012-12-20 | 2018-11-09 | Пфайзер Инк. | Способ гликоконъюгации |
| ITMI20130142A1 (it) | 2013-01-31 | 2014-08-01 | Biosynth Srl | Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati |
| US20150079132A1 (en) * | 2013-09-17 | 2015-03-19 | Path | Evoking protection against streptotoccus pneumoniae incorporating b-cell and t-cell pneumococcal protein antigens and pneumococcal polysaccharides delivered concomitantly |
| CN103495161B (zh) | 2013-10-08 | 2019-06-18 | 江苏康泰生物医学技术有限公司 | 一种多元肺炎球菌荚膜多糖-蛋白质结合物的混合物及其制备方法 |
| FI3583947T3 (fi) * | 2014-01-21 | 2023-10-12 | Pfizer | Streptococcus pneumoniaen kapselipolysakkaridit ja niiden konjugaatit |
| US11160855B2 (en) * | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| IL312327B2 (en) * | 2014-01-21 | 2026-02-01 | Pfizer | Immunogenic preparations comprising conjugated capsular saccharide antigens and their uses |
| BR112016015835B1 (pt) * | 2014-01-21 | 2023-12-26 | Pfizer Inc | Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae |
| ES2930318T3 (es) | 2014-02-14 | 2022-12-09 | Pfizer | Conjugados glucoproteicos inmunogénicos |
| WO2016046420A1 (en) * | 2014-09-26 | 2016-03-31 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Vaccines against streptococcus pneumoniae serotype 8 |
| PL3244917T3 (pl) | 2015-01-15 | 2023-07-17 | Pfizer Inc. | Kompozycje immunogenne do zastosowania w szczepionkach przeciwko pneumokokom |
| WO2016168324A1 (en) * | 2015-04-13 | 2016-10-20 | University Of Maryland, Baltimore | Compositions and methods for producing bacterial conjugate vaccines |
| RS61440B1 (sr) * | 2015-06-23 | 2021-03-31 | Biological E Ltd | Multivalentna pneumokokna konjugatna vakcina |
| KR20250058066A (ko) * | 2015-07-21 | 2025-04-29 | 화이자 인코포레이티드 | 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도 |
| EP3474890B1 (en) * | 2016-06-22 | 2026-05-06 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Pneumococcal polysaccharide-protein conjugate composition |
| EP3493837B1 (en) * | 2016-08-05 | 2022-08-31 | Sanofi Pasteur, Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| IL267709B2 (en) * | 2016-12-30 | 2025-04-01 | Vaxcyte Inc | Polypeptide-antigen conjugates with unnatural amino acids |
| US11951165B2 (en) * | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| BR112019014833A2 (pt) * | 2017-01-20 | 2020-04-14 | Pfizer | composições imunogênicas para uso em vacinas pneumococais |
| JP7680185B2 (ja) * | 2017-02-24 | 2025-05-20 | メルク・シャープ・アンド・ドーム・エルエルシー | 肺炎連鎖球菌多糖-タンパク質コンジュゲートの免疫原性の増強 |
| CN110392690B (zh) * | 2017-02-24 | 2024-01-30 | 默沙东有限责任公司 | 肺炎球菌缀合物疫苗制剂 |
| WO2018169303A1 (ko) * | 2017-03-15 | 2018-09-20 | 주식회사 엘지화학 | 다가 폐렴구균 백신 조성물 |
| MX2019014829A (es) * | 2017-06-10 | 2020-08-17 | Inventprise Llc | Vacunas de conjugado multivalente con polisacáridos de conjugado bivalente o multivalente que proporcionan inmunogenicidad y avidez mejoradas. |
| EP3691677A4 (en) * | 2017-10-04 | 2021-07-07 | Pogona, Llc | COMPOSITIONS OF SACCHARIDE-POLYPEPTIDE CONJUGATES AND THEIR METHODS OF USE |
| EP3720483B1 (en) * | 2017-12-06 | 2025-11-19 | Merck Sharp & Dohme LLC | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
-
2016
- 2016-07-18 KR KR1020257013114A patent/KR20250058066A/ko active Pending
- 2016-07-18 EP EP16741695.7A patent/EP3325008B1/en active Active
- 2016-07-18 WO PCT/IB2016/054217 patent/WO2017013548A1/en not_active Ceased
- 2016-07-18 EP EP25198451.4A patent/EP4649956A3/en active Pending
- 2016-07-18 PE PE2018000092A patent/PE20180657A1/es unknown
- 2016-07-18 TW TW105122614A patent/TWI684460B/zh not_active IP Right Cessation
- 2016-07-18 MY MYPI2018700062A patent/MY192183A/en unknown
- 2016-07-18 JP JP2018502252A patent/JP6994453B2/ja active Active
- 2016-07-18 IL IL303998A patent/IL303998A/en unknown
- 2016-07-18 MX MX2018000867A patent/MX388869B/es unknown
- 2016-07-18 TW TW109137693A patent/TWI756893B/zh not_active IP Right Cessation
- 2016-07-18 KR KR1020187004595A patent/KR102225282B1/ko active Active
- 2016-07-18 TW TW107106645A patent/TWI684461B/zh not_active IP Right Cessation
- 2016-07-18 KR KR1020237013256A patent/KR102800419B1/ko active Active
- 2016-07-18 CN CN202610509233.7A patent/CN122399004A/zh active Pending
- 2016-07-18 RU RU2018100123A patent/RU2721128C2/ru active
- 2016-07-18 AU AU2016295566A patent/AU2016295566B2/en not_active Ceased
- 2016-07-18 HK HK19100160.3A patent/HK1257816A1/zh unknown
- 2016-07-18 CN CN201680054602.2A patent/CN108367063A/zh active Pending
- 2016-07-18 NZ NZ739007A patent/NZ739007A/en not_active IP Right Cessation
- 2016-07-18 CA CA2936378A patent/CA2936378A1/en active Pending
- 2016-07-18 KR KR1020217006257A patent/KR20210027523A/ko not_active Ceased
- 2016-07-18 TW TW108111336A patent/TWI720448B/zh not_active IP Right Cessation
- 2016-07-18 SG SG10202005253TA patent/SG10202005253TA/en unknown
- 2016-07-18 PE PE2023001198A patent/PE20240927A1/es unknown
- 2016-07-18 ES ES16741695T patent/ES3050314T3/es active Active
- 2016-07-18 BR BR112018000087-6A patent/BR112018000087A2/pt not_active Application Discontinuation
- 2016-07-20 AR ARP160102194A patent/AR105402A1/es not_active Application Discontinuation
- 2016-07-20 US US15/214,693 patent/US10124050B2/en active Active
-
2017
- 2017-12-28 IL IL256645A patent/IL256645A/en unknown
-
2018
- 2018-01-04 PH PH12018500037A patent/PH12018500037A1/en unknown
- 2018-01-10 ZA ZA2018/00197A patent/ZA201800197B/en unknown
- 2018-01-19 CO CONC2018/0000503A patent/CO2018000503A2/es unknown
- 2018-01-19 MX MX2021015775A patent/MX2021015775A/es unknown
- 2018-09-25 US US16/140,934 patent/US11020469B2/en active Active
-
2019
- 2019-06-06 ZA ZA2019/03620A patent/ZA201903620B/en unknown
- 2019-07-26 AU AU2019208271A patent/AU2019208271B2/en not_active Ceased
-
2021
- 2021-04-27 US US17/241,603 patent/US20210260177A1/en not_active Abandoned
- 2021-12-13 JP JP2021201968A patent/JP7268125B2/ja active Active
-
2023
- 2023-04-20 JP JP2023069532A patent/JP2023093636A/ja active Pending
-
2024
- 2024-03-19 US US18/609,596 patent/US20250009864A1/en not_active Abandoned
-
2025
- 2025-05-09 JP JP2025078497A patent/JP2025122002A/ja active Pending
- 2025-06-17 US US19/240,698 patent/US20260048112A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550318A1 (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| MX2021015775A (es) | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos. | |
| MX2019008564A (es) | Composiciones inmunogenicas para su uso en vacunas neumococicas. | |
| MX395525B (es) | Composiciones inmunogenicas para usar en vacunas neumococicas. | |
| BR112018007812A2 (pt) | polissacarídeo capsular, processo para preparar um polissacarídeo capsular e para fabricar uma vacina, composição imunogênica, vacina, métodos para tratamento ou prevenção de uma infecção, para imunizar um hospedeiro humano e para induzir uma resposta imune, e, uso de uma composição imunogênica. | |
| MX2016000099A (es) | Vacunas sinteticas contra streptococcus pneumoniae tipo 1. | |
| WO2016198170A8 (en) | Vaccines against streptococcus pneumoniae serotype 5 | |
| BR112017022755A2 (pt) | formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual | |
| JOP20190038B1 (ar) | تركيب اقتراني من السكر المتعدد لكبسولة بكتيريا المكورات الرئوية وبروتين حامل واستخداماته | |
| PH12018501205A1 (en) | Synthetic vaccines against streptococcus pneumoniae serotype 2 | |
| MX2018008415A (es) | Cepas de vacuna de brachyspira hyodysenteriae. | |
| MX2021015155A (es) | Polisacaridos de ramnosa. | |
| BR112022002094A2 (pt) | Composição imunogênica | |
| AR132428A1 (es) | Composiciones inmunógenas que comprenden antígenos de sacárido capsular conjugados y usos de estos | |
| CO2025006472A2 (es) | Composiciones inmunógenas que comprenden antígenos de sacárido capsular conjugados y sus usos | |
| PE20252774A1 (es) | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos |